Department of Surgery, Elisabeth-Tweesteden Hospital, Tilburg, The Netherlands.
School for Oncology and Developmental Biology, Faculty of Health Medicine and Life Sciences, Research Institute GROW, Maastricht University, Maastricht, The Netherlands.
Int J Cancer. 2019 Nov 15;145(10):2720-2727. doi: 10.1002/ijc.32353. Epub 2019 May 2.
Between January 1, 2011, and December 31, 2016, we studied the incidence, management and outcome of high-risk breast lesions in a consecutive series of 376,519 screens of women who received biennial screening mammography. During the 6-year period covered by the study, the proportion of women who underwent core needle biopsy (CNB) after recall remained fairly stable, ranging from 39.2% to 48.1% (mean: 44.2%, 5,212/11,783), whereas the proportion of high-risk lesions at CNB (i.e., flat epithelial atypia, atypical ductal hyperplasia, lobular carcinoma in situ and papillary lesions) gradually increased from 3.2% (25/775) in 2011 to 9.5% (86/901) in 2016 (p < 0.001). The mean proportion of high-risk lesions at CNB that were subsequently treated with diagnostic surgical excision was 51.4% (169/329) and varied between 41.0% and 64.3% through the years, but the excision rate for high-risk lesions per 1,000 screens and per 100 recalls increased from 0.25 (2011) to 0.70 (2016; p < 0.001) and from 0.81 (2011) to 2.50 (2016; p < 0.001), respectively. The proportion of all diagnostic surgical excisions showing in situ or invasive breast cancer was 29.0% (49/169) and varied from 22.2% (8/36) in 2014 to 38.5% (5/13) in 2011. In conclusion, the proportion of high-risk lesions at CNB tripled in a 6-year period, with a concomitant increased excision rate for these lesions. As the proportion of surgical excisions showing in situ or invasive breast cancer did not increase, a rising number of screened women underwent invasive surgical excision with benign outcome.
2011 年 1 月 1 日至 2016 年 12 月 31 日期间,我们对连续 376519 例接受两年一次乳腺筛查的女性的高危乳腺病变的发病率、处理方法和结局进行了研究。在研究涵盖的 6 年期间,经召回后行核心针活检(CNB)的女性比例相当稳定,范围为 39.2%至 48.1%(均值:44.2%,5212/11783),而 CNB 处的高危病变比例(即扁平上皮不典型增生、非典型导管增生、小叶原位癌和乳头状病变)逐渐从 2011 年的 3.2%(25/775)增加到 2016 年的 9.5%(86/901)(p<0.001)。CNB 后行诊断性外科切除的高危病变的平均比例为 51.4%(169/329),且多年来在 41.0%至 64.3%之间变化,但每 1000 次筛查和每 100 次召回中高危病变的切除率从 0.25(2011 年)增加到 0.70(2016 年;p<0.001)和从 0.81(2011 年)增加到 2.50(2016 年;p<0.001)。所有诊断性外科切除标本中显示原位或浸润性乳腺癌的比例为 29.0%(49/169),且在 2014 年为 22.2%(8/36),而在 2011 年为 38.5%(5/13)。总之,CNB 处高危病变的比例在 6 年内增加了两倍,同时这些病变的切除率也增加了。由于显示原位或浸润性乳腺癌的外科切除比例没有增加,因此越来越多的接受筛查的女性接受了良性结局的侵入性外科切除。